Osimertinib in EGFR Mutation-Positive Advanced NSCLC

被引：25
|
作者：
不详
机构：
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 13期
关键词：
PARAGANGLIOMA;
D O I：
10.1056/NEJMc1801669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1260 / 1261
页数：2
相关论文
共 50 条
  • [21] Management of CNS metastases in patients with EGFR mutation-positive NSCLC
    Shetty, Vijith
    Babu, Suresh
    INDIAN JOURNAL OF CANCER, 2019, 56 (05) : 31 - 37
  • [22] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [23] Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC
    Roeper, Julia
    Kurz, Sylke
    Grohe, Christian
    Griesinger, Frank
    FUTURE ONCOLOGY, 2020, 17 (04) : 471 - 486
  • [24] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [25] Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm plus ) NSCLC: Analysis of Time on Treatment and OS
    Park, K.
    Tan, E.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T.
    Hirsh, V.
    Yang, J. C.
    Schuler, M.
    Yamamoto, N.
    Sequist, L.
    Wu, Y.
    Zhou, C.
    Ehrnrooth, E.
    Marten, A.
    Tang, W.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2215 - S2216
  • [26] A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
    Chihara, Yusuke
    Takeda, Takayuki
    Goto, Yasuhiro
    Nakamura, Yoichi
    Tsuchiya-Kawano, Yuko
    Nakao, Akira
    Onoi, Keisuke
    Hibino, Makoto
    Fukuda, Minoru
    Honda, Ryoichi
    Yamada, Takahiro
    Taniguchi, Ryusuke
    Sakamoto, Sinjiro
    Date, Koji
    Nagashima, Seiji
    Tanzawa, Shigeru
    Minato, Koichi
    Nakatani, Koichi
    Izumi, Miiru
    Shimose, Takayuki
    Kishimoto, Junji
    Uchino, Junji
    Takayama, Koichi
    ONCOLOGIST, 2022, 27 (11): : 903 - E834
  • [27] Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC
    Thongprasert, S.
    Geater, S. L.
    Clement, D.
    Abdelaziz, A.
    Reyes-Igama, J.
    Jovanovic, D.
    Alexandru, A.
    Schenker, M.
    Sriuranpong, V.
    Serwatowski, P.
    Suresh, S.
    Cseh, A.
    Gaafar, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 146 - 146
  • [29] Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC
    Hamaguchi, Reo
    Okamoto, Toshihiro
    Sato, Masaaki
    Hasegawa, Michiko
    Wada, Hiromi
    ANTICANCER RESEARCH, 2017, 37 (09) : 5141 - 5145
  • [30] Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
    Harvey, R. Donald
    Adams, Val R.
    Beardslee, Tyler
    Medina, Patrick
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (06) : 1461 - 1474
12345